Parkinson's Clinical Trial Companion Navigating Clinical Trials | Page 54

Index
Adverse event
15, 44 Dyskinesia
10, 19, 24 Intervention
11, 16, 43, 47
Alpha-synuclein
10, 29, 44, 46 Efficacy
8, 10, 45 Interventional trial
16, 17, 47
Arm
44 Eligibility criteria
45 Longitudinal study
47
Baseline data
44 European Medicines Agency
(EMA)
8, 10, 46 LRRK2
31, 35, 47
Biomarker
12, 21, 43, 44, 45, 47, 48
Lumbar puncture
17, 47
Precision medicine
10, 31, 39, 48
Pre-clinical
7, 48
Principal investigator
9, 48
Protocol
8, 9, 16, 33, 48
Familial Parkinson’s disease
41, 46 Magnetic Resonance Imaging
(MRI)
47 Fox Insight
8, 13, 24, 26, 43 Motor symptoms
7, 21, 25, 26 Recruiting
5, 14, 15, 22, 42, 48
Clinical study
3, 7, 11, 13, 15, 20, 21, 29, 41, 45 Fox Trial Finder
5, 13, 14, 15, 41, 42 Multicenter trial
8, 47 Repurposing
48
Clinical trial
2-3, 7-9, 10, 11, 13, 15-17, 19-21,
23, 31, 34, 40-41, 45 Gaucher disease
46 Neuroprotective treatment
40, 47 SNCA
29, 31, 48
GBA
31, 32, 46 Neuroregenerative treatment
47 Statistical significance
48
Gene
11, 29, 30, 31, 32, 33, 34, 35,
36, 37, 38, 39, 46 New Drug Application (NDA)
8, 47 Study funder
16, 48
Non-motor symptoms
7, 11, 21, 25 Study sponsor
48
Observational studies
8, 11, 21, 24, 27, 41, 47 Symptomatic therapy
10, 27, 48
Open label
47 Telemedicine
13, 48
Outcome measure
47 Tolerability
48
Patient-reported Outcomes
(PROs)
47 Unified Parkinson’s Disease
Rating Scale (UPDRS)
49
Placebo
8, 15, 16, 21, 40, 47 U.S. Food and Drug
Administration (FDA)
8, 10, 49
Blinding/Blind or “Double-blind”
8, 44, 47
Breakthrough therapy
designation
10, 44
Cohort
45
Computed Tomography (CT)
Scan
45
Control volunteer
8, 11, 12, 26, 33, 45
Controlled trial
8-9, 45
DaTscan
45
De novo Parkinson’s
21, 45
Deep brain stimulation
2, 4, 24, 26
Digital health (see also
telemedicine, virtual study,
wearable)
45, 49
Dementia
10, 19, 24
Disease-modifying therapies
8, 10, 20, 21, 45
52
Exclusion criteria
11, 16, 24, 45, 46
Parkinson’s Progression Marker’s
Initiative (PPMI)
12, 37, 43
Genetic mutation
30, 31, 32, 33, 34, 37, 38, 39, 46
Genetic counselor
30, 34, 35, 36. 37, 38, 39, 46
Genetic Information
Nondiscrimination Act (GINA)
34, 37, 38
Genetic testing
29, 32, 33, 34, 36, 37, 38, 39, 40,
46
Hoehn and Yahr (H&Y) scale
46
Idiopathic Parkinson’s disease
46
Inclusion criteria
11, 16, 24, 46
Informed consent
9, 15, 34, 46
Institutional Review Board (IRB)
9, 46
Navigating Clinical Trials: A Guide for Parkinson’s Patients and Families
Placebo-controlled
9, 16, 21, 48
Placebo effect
48
Positron Emission Tomography
(PET) scan
48
Randomized
8, 15, 16, 48
Virtual Study
49
Wearable
10, 13, 49